Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.

For women 30 years of age or older (past the age at which new HPV infections peak), HPV and cytologic cotesting every 5 years is now an accepted alternative to cytologic testing alone every 3 years, since the risk of cervical cancer is very low in the years after a negative HPV test.

[1]  B. Thiers.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2009 .

[2]  P. Martin-Hirsch,et al.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. , 2009, Cancer treatment reviews.

[3]  H. zur Hausen,et al.  Papillomaviruses in the causation of human cancers - a brief historical account. , 2009, Virology.

[4]  Diane Solomon,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[5]  C. Wheeler,et al.  Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[6]  V. Beral,et al.  Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies , 2007, The Lancet.

[7]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[8]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[9]  M. Schiffman,et al.  Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines , 2013, Journal of lower genital tract disease.

[10]  Chien-Jen Chen,et al.  Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. , 2011, Journal of the National Cancer Institute.

[11]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[12]  M. Schiffman,et al.  2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2013, Journal of lower genital tract disease.

[13]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[14]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012, CA: a cancer journal for clinicians.

[15]  J. Doorbar,et al.  Molecular biology of human papillomavirus infection and cervical cancer. , 2006, Clinical science.

[16]  S. Wacholder,et al.  Low risk of type‐specific carcinogenic HPV re‐appearance with subsequent cervical intraepithelial neoplasia grade 2/3 , 2012, International journal of cancer.

[17]  J. Felix,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[18]  Shalini L Kulasingam,et al.  Screening for Cervical Cancer: A Modeling Study for the US Preventive Services Task Force , 2013, Journal of lower genital tract disease.

[19]  V. Beral,et al.  Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies , 2006, International journal of cancer.

[20]  V. Moyer,et al.  Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[21]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results , 2013, Journal of lower genital tract disease.

[22]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[23]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[24]  Marc Arbyn,et al.  Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors: A Randomized Controlled Trial , 2010 .

[25]  Diane Solomon,et al.  Number of Cervical Biopsies and Sensitivity of Colposcopy , 2006, Obstetrics and gynecology.

[26]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[27]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[28]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[29]  J. Green,et al.  Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies , 2007, International journal of cancer.

[30]  ACOG Practice Bulletin Number 131: Screening for cervical cancer. , 2012, Obstetrics and gynecology.

[31]  M. Hudgens,et al.  Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study , 2011, International journal of cancer.

[32]  Diane Solomon,et al.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. , 2010, Journal of the National Cancer Institute.

[33]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[34]  J. T. Cox,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. , 2012, Journal of lower genital tract disease.

[35]  S. Wacholder,et al.  Human papillomavirus testing in the prevention of cervical cancer. , 2011, Journal of the National Cancer Institute.

[36]  R. DeSalle,et al.  The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.

[37]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[38]  J. Berkhof,et al.  HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications , 2012, British Journal of Cancer.

[39]  Xavier Castellsagué,et al.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. , 2006, Journal of the National Cancer Institute.

[40]  D. Solomon,et al.  Cervical Cancer Screening Rates in the United States and the Potential Impact of Implementation of Screening Guidelines , 2007, CA: a cancer journal for clinicians.

[41]  M. Einstein,et al.  Clinical validation of the cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology , 2011 .

[42]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[43]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[44]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[45]  M. Schiffman,et al.  Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results , 2013, Journal of lower genital tract disease.

[46]  M. Schiffman,et al.  Heterogeneity in CIN3 diagnosis. , 2008, The Lancet. Oncology.

[47]  Diane Solomon,et al.  Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. , 2011, Cancer discovery.

[48]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[49]  Robert P Fields.  Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[50]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.